Results Over the first year the team reviewed 351 patients with suspected CAP; 50 had a chest radiograph reported as clear and were excluded, leaving 301 for analysis. Length of hospital stay (LOS) was reduced when compared with preintervention after adjustment for disease severity using CURB-65 (low severity, 2.8 vs 4.4 days, p<0.01; moderate severity, 4.3 vs 7.6 days, p<0.01; high severity, 6.0 vs 8.9 days, p=0.07). Readmission rate at 30 days was unchanged (54/301, 17.9% vs. 50/324, 15.4%, p=0.45). Early supported discharge was appropriate in 51/172 (30.0%) patients with low severity CAP; in this group median LOS was 1.4 days and readmission rate 6/51 (11.8%). A positive microbiological diagnosis was made in 69/301 (22.9%) patients compared with 16/324 (4.9%) pre-intervention; 60/301 (19.9%) had a positive POC test with a result available within the acute admitting area. As a result, broad spectrum antibiotic regimens were streamlined in 43 (14.3%) patients. Conclusion A dedicated respiratory infections team can significantly reduce LOS for patients admitted with CAP. A robust microbiological diagnosis early in the admission episode Results in an improvement in antibiotic stewardship. Introduction and Objectives Alcohol consumption is a well-recognised risk factor for a range of diseases, but there is relatively little knowledge on the association between alcohol consumption and respiratory disease risk. We present systematic reviews of alcohol effects on Adult Respiratory Distress Syndrome, asthma, COPD, community acquired pneumonia, obstructive sleep apnoea and tuberculosis. Methods Systematic reviews identified comparative observational studies listed on Medline, EMBASE and Web of Science, published between 1985 and December 2015, with the exception of tuberculosis, for which we performed a separate search from 2005 to 2017. The reference lists of the eligible studies were also searched. We imposed no language restrictions. Random effects meta-analysis was used to estimate pooled effect sizes with 95% confidence intervals (CI). Heterogeneity was explored using subgroup analyses. Funnel plots and Egger's asymmetry test were used for the assessment of publication bias. Results A total of 120 papers were included in these reviews (see Table 1 ). Our reviews confirmed an approximate doubling in the risk of CAP among drinkers. In addition, we found that there is an 8% increase in the risk of CAP for every 10-20 grams higher alcohol intake per day. Also, heavy alcohol consumption was found to significantly increase the odds of ARDS/ALI. Furthermore, a subgroup analysis indicated that this association was primarily due to alcohol abuse. Alcohol consumption increased the risk of TB between 2 and 3-fold, depending on study design. We found no evidence of an effect of alcohol consumption on the risk of asthma and COPD.
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Conclusions Our review highlights that high alcohol intake is linked to the risks of several respiratory diseases, and that reducing alcohol intake may have an important role to play in respiratory disease prevention. Discussion 109 (73%) patients with COPD and hypercapnic respiratory failure continued using NIV after set up. Our data demonstrates lower body mass index was significantly associated with surviving<12 months after starting NIV. Patients who survived more than 12 months showed a non-significant trend to be male, younger and use NIV for more than 4 hours each night at higher inspiratory pressures. An unexpected finding was that patients intolerant of NIV showed a trend to longer survival, compared to those who continued with NIV. This may be due to the small number of patients with full data, or that 50% of these patients had stable hypercapnic respiratory failure at NIV initiation, compared to 25% in the patients who used NIV. Conclusions These observations highlight the need for careful patient selection when considering which patients with COPD may benefit from home NIV, an awareness of the different features that may contribute to survival, and subsequent attention to ventilator settings and compliance once the treatment has begun.
P124 EARLY EXPERIENCE WITH 2-WAY REMOTE MONITORING FOR THE INITIATION OF VOLUME-ASSURED HOME NON-INVASIVE VENTILATION
Introduction The prevalence of conditions requiring nocturnal breathing support is increasing. 2-way remote monitoring via a cloud based system provides access to home non-invasive ventilation (NIV) data, highlights therapy issues and facilitates prescription changes to optimise NIV and potentially rationalise patient follow up. Remote-adjustable volume-assured NIV modes with auto-EPAP and intelligent backup rates offer prospects for improved NIV titration. We have adopted these emerging technologies with aim of improving patient outcomes and service efficiency. Interrogation of remote monitoring NIV data will provide insights to the utility of new NIV modes. 
